Viveve Medical (VIVE) 10-K 15 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 08, 2019	Jun. 29, 2018
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		46,364,570
Entity Public Float			$ 68,489,676
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 29,523,000	$ 20,730,000
Accounts receivable, net of allowance for doubtful accounts of $284 and $221 as of December 31, 2018 and 2017, respectively	5,704,000	6,213,000
Inventory	4,119,000	2,390,000
Prepaid expenses and other current assets	2,558,000	2,741,000
Total current assets	41,904,000	32,074,000
Property and equipment, net	2,916,000	1,303,000
Investment in limited liability company	1,843,000	2,500,000
Other assets	171,000	202,000
Total assets	46,834,000	36,079,000
Current liabilities:
Accounts payable	3,994,000	4,799,000
Accrued liabilities	6,766,000	4,605,000
Total current liabilities	10,760,000	9,404,000
Note payable, noncurrent portion	30,528,000	28,948,000
Other noncurrent liabilities	634,000	327,000
Total liabilities	41,922,000	38,679,000
Commitments and contingences (Note 7)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2018 and 2017; 46,363,945 and 19,503,558 shares issued and outstanding as of December 31, 2018 and 2017, respectively	5,000	2,000
Additional paid-in capital	160,292,000	102,979,000
Accumulated deficit	(155,385,000)	(105,581,000)
Total stockholders’ equity (deficit)	4,912,000	(2,600,000)
Total liabilities and stockholders’ equity (deficit)	$ 46,834,000	$ 36,079,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable, allowance for doubtful accounts	$ 284	$ 221
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	46,363,945	19,503,558
Common stock, shares outstanding (in shares)	46,363,945	19,503,558

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 18,517	$ 15,288
Cost of revenue	11,197	7,844
Gross profit	7,320	7,444
Operating expenses:
Research and development	13,716	12,343
Selling, general and administrative	38,569	28,831
Total operating expenses	52,285	41,174
Loss from operations	(44,965)	(33,730)
Interest expense, net	(4,372)	(3,169)
Other income (expense), net	13	(60)
Net loss from consolidated companies	(49,324)	(36,959)
Loss from minority interest in limited liability company	(657)
Comprehensive and net loss	$ (49,981)	$ (36,959)
Net loss per share:
Basic and diluted (in dollars per share)	$ (1.61)	$ (2.11)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	31,059,483	17,496,942

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	March 2017 Offering [Member]Common Stock [Member]	March 2017 Offering [Member]Additional Paid-in Capital [Member]	March 2017 Offering [Member]	November 2017 ATM Facility [Member]Common Stock [Member]	November 2017 ATM Facility [Member]Additional Paid-in Capital [Member]	November 2017 ATM Facility [Member]	December 2018 Offering [Member]Common Stock [Member]	December 2018 Offering [Member]Additional Paid-in Capital [Member]	December 2018 Offering [Member]Retained Earnings [Member]	December 2018 Offering [Member]	February 2018 Offering [Member]Common Stock [Member]	February 2018 Offering [Member]Additional Paid-in Capital [Member]	February 2018 Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2016														10,661,201
Balances at Dec. 31, 2016														$ 1	$ 68,216	$ (68,622)	$ (405)
Stock offering, net of issuance costs (in shares)	8,625,000			59,249		59,249
Stock offering, net of issuance costs	$ 1	$ 31,439	$ 31,440		$ 125	$ 125
Stock-based compensation expense															1,646		1,646
Issuance of warrants in connection with note payable															940		940
Issuance of restricted common shares (in shares)														35,000
Issuance of restricted common shares															260		260
Issuance of restricted stock awards to directors, employees and consultants (in shares)														77,783
Issuance of restricted stock awards to directors, employees and consultants															226		226
Issuance of common shares from employee stock purchase plan (in shares)														17,894
Issuance of common shares from employee stock purchase plan															76		$ 76
Exercise of stock options (in shares)														7,730			7,730
Exercise of stock options															31		$ 31
Exercise of warrants (in shares)														4,701
Exercise of warrants															20		20
Cashless exercise of warrant (in shares)														15,000
Net loss																(36,959)	(36,959)
Balances (in shares) at Dec. 31, 2017														19,503,558
Balances at Dec. 31, 2017														$ 2	102,979	(105,581)	(2,600)
Stock offering, net of issuance costs (in shares)				277,249		277,249	14,728,504				11,500,000
Stock offering, net of issuance costs					$ 1,193	$ 1,193	$ 2	$ 20,383		$ 20,385	$ 1	$ 32,213	$ 32,214
Stock-based compensation expense															2,699		2,699
Issuance of warrants in connection with note payable
Issuance of restricted common shares (in shares)														100,000
Issuance of restricted common shares															256		256
Issuance of restricted stock awards to directors, employees and consultants (in shares)														128,847
Issuance of restricted stock awards to directors, employees and consultants															336		336
Issuance of common shares from employee stock purchase plan (in shares)														125,787
Issuance of common shares from employee stock purchase plan															233		$ 233
Exercise of stock options (in shares)
Net loss																(49,981)	$ (49,981)
Cumulative effect adjustment from adoption of new accounting standard – ASC 606 at Dec. 31, 2017																177	177
Balances (in shares) at Dec. 31, 2018														46,363,945
Balances at Dec. 31, 2018														$ 5	$ 160,292	$ (155,385)	$ 4,912

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (49,981,000)	$ (36,959,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for (recovery from) doubtful accounts	179,000	(221,000)
Depreciation and amortization	786,000	449,000
Stock-based compensation	3,035,000	1,872,000
Fair value of common stock issued	256,000	260,000
Non-cash interest expense	1,580,000	1,049,000
Loss from minority interest in limited liability company	657,000
Changes in assets and liabilities:
Accounts receivable	330,000	(3,901,000)
Inventory	(1,986,000)	(67,000)
Prepaid expenses and other current assets	183,000	(1,675,000)
Other noncurrent assets	31,000	(66,000)
Accounts payable	(805,000)	1,713,000
Accrued and other liabilities	2,143,000	2,419,000
Other noncurrent liabilities	502,000	274,000
Net cash used in operating activities	(43,090,000)	(34,853,000)
Cash flows from investing activities:
Purchase of property and equipment	(2,142,000)	(905,000)
Investment in limited liability company		(2,500,000)
Net cash used in investing activities	(2,142,000)	(3,405,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	53,792,000	31,565,000
Proceeds from note payable		29,210,000
Repayments of note payable		(10,000,000)
Proceeds from issuance of common shares from employee stock purchase plan	233,000	76,000
Proceeds from exercise of stock options		31,000
Proceeds from exercise of warrant		20,000
Net cash provided by financing activities	54,025,000	50,902,000
Net increase in cash and cash equivalents	8,793,000	12,644,000
Cash and cash equivalents - beginning of period	20,730,000	8,086,000
Cash and cash equivalents - end of period	29,523,000	20,730,000
Supplemental disclosure:
Cash paid for interest	2,673,000	2,066,000
Cash paid for income taxes	2,000
Supplemental disclosure of cash flow information as of end of period:
Issuance of warrants in connection with note payable		940,000
Issuance of note payable in settlement of accrued interest	1,256,000	495,000
Net transfer of equipment between inventory and property and equipment	$ 257,000	$ 364,000

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) competes in the women’s intimate health industry in some countries by marketing the Viveve System as a way to improve the overall well-being and quality of life of women suffering from vaginal introital laxity, for improved sexual function, or stress urinary incontinence, depending on the relevant country-specific clearance or approval. In the United States, the Viveve System is currently indicated for use in general surgical procedures for electrocoagulation and hemostasis. Public Offerings In December 2018, “December 2018 14,728,504 $1.50 $22,093,000. $20,385,000. In February 2018, “February 2018 11,500,000 $3.00 $34,500,000. $32,214,000. The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, may $25,000,000 “November 2017 2018 2017, 277,249 $1,193,000 59,249 $125,000, December 31, 2018, 336,498 November 2017 $1,318,000. In March 2017, “March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. Liquidity and Management Plans The Company has adopted FASB Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of December 31, 2018, $155,385,000 $29,523,000 $31,144,000. $43,090,000 December 31, 2018. March 31, 2020. not one January 2019, November 2017 To fund further operations, the Company will need to raise additional capital. The Company may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the FDA or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2018, one 21% December 31, 2017, two 35% There are no 10% December 31, 2018 2017. As of December 31, 2018, three 54% December 31, 2017, two 57% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $284,000 $221,000 December 31, 2018 2017, Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2018 $3,232,000 $887,000 December 31, 2017 $1,990,000 $40,000 first first not As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2018 2017. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2018 2017. $686,000, not December 31,2018. No December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one December 31, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the year ended December 31, 2018 December 31, 2018 For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (1.61 ) $ (1.63 ) $ 0.02 Weighted average shares 31,059,483 31,059,483 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3) ( 1 Change relates to the current portion of deferred revenue in connection with the extended warranties not 606, 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $749,000 December 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). Year Ended December 31, 2018 2017 United States $ 13,606 11,004 Asia Pacific 2,891 3,178 Europe and Middle East 1,369 667 Canada 563 79 Latin America 51 360 Other 37 - Total $ 18,517 $ 15,288 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2018 2017, no Product Warranty The Company’s products are generally subject to warranties between one three not Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2018 2017. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2018 2017. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2018 2017, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2018 2017 Stock options to purchase common stock 4,014,475 2,694,224 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 57,500 10,000 Recently Issued and Adopted Accounting Standards In February 2016, No. 2016 02, 842 December 15, 2018, July 2018, January 1, 2019, 12 not In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not In June 2018, 2018 07, 718 718 718 December 15, 2018, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 2018 2017. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2018 2017 There were no

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2018 2017 Life December 31, (in years) 2018 2017 Medical equipment 5 $ 3,571 $ 1,299 Computer equipment 3 309 193 Leasehold Improvements 3 121 200 Furniture and fixtures 7 403 340 Software 3 25 - 4,429 2,032 Less: Accumulated depreciation and amortization (1,513 ) (729 ) Property and equipment, net $ 2,916 $ 1,303 Depreciation and amortization expense for the years ended December 31, 2018 2017 $786,000 $449,000,

Note 5 - Investment in Limited

Note 5 - Investment in Limited Liability Company	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	5. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not December 31, 2018 2017, 3,300 1,200 $327,000 $89,000, December 31, 2018, 4,500 $416,000. $337,000 $94,000 December 31, 2018 2017, In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not December 31, 2018, 9% three December 31, 2018, $657,000 December 31, 2017,

Note 6 - Accrued Liabilities

Note 6 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2018 2017 December 31, December 31, 2018 2017 Accrued sales commission $ 1,743 $ 1,067 Accrued professional fees 978 562 Accrued bonuses 837 1,597 Accrued interest 683 447 Customer contracts liabilities 686 - Accrued payroll and other related expenses 877 488 Travel and entertainment 280 156 Accrued sales & use tax 259 149 Accrued clinical trial costs 84 30 Other accruals 339 109 Total accrued liabilities $ 6,766 $ 4,605

Note 7 - Note Payable

Note 7 - Note Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	7 . Note Payable On June 20, 2016, January 13, 2017 ( “2016 $10,000,000 two $7,500,000 $2,500,000. $10,000,000 June 20, 2016. 2016 4.00% 2016 May 2017. In connection with the 2016 10 100,402 $4.98 8 On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, December 31, 2018 2017, $1,256,000 $495,000, 5.0% December 31, 2018, $484,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 December 31, 2018, As of December 31, 2018 2017, $30,528,000 $28,948,000 2017 In connection with the 2017 two 10 222,049 $9.50 8 As of December 31, 2018, Year Ending December 31, 2019 $ 2,778 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 47,878 Less: Amount representing interest (16,127 ) Present value of obligations 31,751 Less: Unamortized debt discount (1,223 ) Note payable, noncurrent portion $ 30,528

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Operating Lease On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the years ended December 31, 2018 2017 $358,000 $442,000, In September 2018, 36 September 20, 2018. $3,000. As of December 31, 2018, Year Ending December 31, 2019 $ 296 2020 143 2021 23 Total minimum lease payments $ 462 Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not Legal Proceedings In December 2018, On June 4, 2018, Under the terms of the Settlement Agreement, the Company received an initial monetary payment to settle the litigation and past claims and an on-going royalty for future sales. Viveve granted to ThermiGen a non-exclusive, non-transferable license to use the Company’s U.S. patent for the current version of ThermiGen’s ThermiVa system (which includes RF generators and consumables). The Company has recorded the monetary payment as a gain on litigation settlement in selling, general and administrative expenses on the consolidated statements of operations during the year ended December 31, 2018.

Note 9 - Common Stock

Note 9 - Common Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Common Stock In December 2018, “December 2018 14,728,504 $1.50 $22,093,000. $20,385,000. In June 2018, 100,000 $2.56 $256,000. In February 2018, February 2018 11,500,000 $3.00 $34,500,000. $32,214,000. Through the November 2017 may $25,000,000 2018 2017, 277,249 $1,193,000 59,249 $125,000, December 31, 2018, 336,498 November 2017 $1,318,000. December 31, 2018, 59,249 November 2017 $125,000. In May 2017, 35,000 $7.42 $260,000. In March 2017, March 2017 8,625,000 $4.00 $34,500,000. $31,440,000. Warrants for Common Stock As of December 31, 2018 2017, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622 In connection with the 2016 100,402 $4.98 $350,000. $90,000, May 2017 2017 December 31, 2017, $371,000 In connection with the 2017 222,049, $9.50 ten $940,000 0%, 55.1%, 2.25% ten $790,000, December 31, 2018 2017, $325,000 $183,000, December 31, 2018, $1,223,000. No September 30, 2014, December 31, 2018 2017, No December 31, 2018 2017. The stock-based compensation expense related to warrants issued was zero December 31, 2018 2017,

Note 10 - Summary of Stock Opti

Note 10 - Summary of Stock Options	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 The 2006 September 23, 2014 2006 2006 December 31, 2018, 2006 38,145 no $9.96 1.3 The 2013 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, 2013 first January, 2013 4% December 23, 2016, 2017 2013 523,209 2,000,000 2,523,209 January 1, 2017. August 15, 2017, 2013 2013 2,523,209 4,000,000 December 6, 2017, 2018 2013 4,000,000 4,914,016 January 1, 2018. As of December 31, 2018, 2013 3,976,330 603,712 $4.50 7.5 Activity under the 2006 2013 Year Ended December 31, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, December 31, 2016 1,909,764 $ 6.19 9.1 $ 211,396 Options granted 1,000,985 $ 5.68 Options exercised (7,730 ) $ 4.02 Options canceled (208,795 ) $ 8.88 Options outstanding, December 31, 2017 2,694,224 $ 5.80 8.6 $ 249,154 Options granted 2,358,559 $ 3.52 Options exercised - $ - Options canceled (1,038,308 ) $ 5.43 Options outstanding, December 31, 2018 4,014,475 $ 4.56 7.4 $ - Vested and exercisable and expected to vest, end of period 3,825,887 $ 4.98 7.3 $ - Vested and exercisable, end of period 1,637,474 $ 5.44 5.0 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of December 31, 2018. The options outstanding and exercisable as of December 31, 2018 Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices Dec 31, 2018 Price Term (Years) Dec 31, 2018 Price $1.75 - $1.97 535,000 $ 1.95 9.4 50,000 $ 1.97 $2.02 - $2.83 180,000 $ 2.40 9.4 11,459 $ 1.97 $3.03 - $3.82 546,876 $ 3.53 9.1 64,090 $ 2.64 $4.30 - $4.97 1,247,318 $ 4.54 7.3 503,934 $ 3.76 $5.01 - $5.67 693,067 $ 5.36 6.8 397,466 $ 4.62 $6.00 - $6.61 490,470 $ 6.04 4.1 412,662 $ 5.34 $7.00 - $7.92 283,599 $ 7.65 7.4 159,718 $ 6.02 $9.92 38,135 $ 9.92 1.3 38,135 $ 7.66 $59.60 - $149.04 10 $ 149.04 2.8 10 $ 9.92 4,014,475 $ 4.56 7.4 1,637,474 $ 5.44 Stock Option Modifications On May 30, 2018, December 31, 2018. May 30, 2018, six three one $97,000 Restricted Stock Awards As of December 31, 2018, 57,500 In December 2018, 40,775 2013 $1.05 40,775 In October 2018, 17,985 2013 $2.48 17,985 In July 2018, 18,278 2013 $2.63 18,278 In June 2018, 50,000 $3.58 two December 31, 2018, zero In April 2018, 14,672 2013 $3.44 14,672 In January 2018, 9,637 2013 $5.19 9,637 In January 2018, 25,000 $5.19 one December 31, 2018, 25,000 In December 2017, 10,000 $4.94 four 1/4 th first December 31, 2018, 2,500 In October 2017, 7,884 2013 $5.55 7,884 In May 2017, 4,797 2013 $7.07 4,797 September 2017, 6,947 2013 $5.58 6,947 2017 Employee Stock Purchase Plan The second 2017 “2017 January 1, 2018 March 31, 2018, 20,744 March 29, 2018 $3.11. third 2017 April 1, 2018 June 30, 2018, 25,618 June 29, 2018 $2.31. fourth 2017 July 1, 2018 September 30, 2018, 28,698 September 28, 2018 $2.24. fifth 2017 October 1, 2018 December 31, 2018, 50,727 December 31, 2018 $0.89. As of December 31, 2018, 2017 256,319 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Year Ended December 31, 2018 2017 Expected term (in years) 0.25 0.25 Average volatility 72% 61% Risk-free interest rate 1.92% 1.06% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 December 31, 2018 2017 $0.89 $1.51 Stock-Based Compensation During the years ended December 31, 2018 2017, 2,146,171 981,110 $2.24 $2.88 no December 31, 2018. December 31, 2017 $31,000. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2018 2017 Expected term (in years) 5 5 Average volatility 73% 59% Risk-free interest rate 2.65% 1.89% Dividend yield 0% 0% During the years ended December 31, 2018 2017, 212,388 19,875 $1.62 $4.09 no December 31, 2018 2017. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2018 2017 Expected term (in years) 9 10 Average volatility 69% 72% Risk-free interest rate 2.69% 2.38% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2018 2017 Year Ended December 31, 2018 2017 Cost of revenue $ 69 $ 19 Research and development 328 252 Selling, general and administrative 2,638 1,601 Total $ 3,035 $ 1,872 As of December 31, 2018, $4,328,328. 2.72

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes No no A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2018 2017 Income tax provision (benefit) at statutory rate (21 )% (34 )% State income taxes, net of federal benefit (4 )% (4 )% Change in valuation allowance 23 % 4 % Effect of tax legislation 0 % 33 % Other 2 % 1 % Effective tax rate 0 % 0 % The components of the Company’s net deferred tax assets and liabilities are as follows (in thousands): December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 31,759 $ 19,699 Capitalized start up costs 3,555 3,963 Research and development credits 951 835 Accruals and reserves 1,272 1,403 Fixed assets and depreciation 69 39 Total deferred tax assets 37,606 25,939 Valuation allowance (37,606 ) (25,939 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on it past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $11,667,000 $1,501,000 December 31, 2018 2017, As of December 31, 2018, $126,893,000 $97,677,000, 2026. The Company also has federal and California research and development tax credits of approximately $830,000 $668,000, 2026 no Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three 382. may 382 no no As of December 31, 2018, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2018 2017 Balance at the beginning of the year $ 397 $ 268 Additions based upon tax positions related to the current year 53 129 Balance at the end of the year $ 450 $ 397 If the ending balance of $450,000 December 31, 2018 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits. On December 22, 2017, 21%, January 1, 2018. The Company is required to recognize the effect on deferred tax assets and liabilities due to a change in tax rates in the period the tax rate change was enacted. The carrying value of the Company’s U.S. deferred taxes is determined by the enacted U.S. corporate income tax rate. Consequently, the reduction in the U.S. corporate income tax rate impacts the carrying value of our deferred tax assets. Under the new corporate income tax rate of 21%, not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2018, 809 37,500 $10,150,000 $7,912,000 December 31, 2018 2017, The Company’s long-lived assets by geographic area were as follows (in thousands): Year Ended December 31, 2018 2017 United States $ 2,851 $ 1,192 Asia Pacific 24 52 Canada 28 46 Latin America 5 12 Europe 8 1 Total $ 2,916 $ 1,303 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date.

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 3 . Subsequent Events In January 2019, 2019 2013 2,043,142 4,914,016 6,957,158 January 1, 2019. In February 2019, no

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new revenue recognition accounting standard, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard On January 1, 2018, 606 606 606” not January 1, 2018. January 1, 2018 606, not 605 605” Previously under ASC 605, 606, not $177,000, $195,000 $18,000 The details for the impact of the adoption of ASC 606 Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 ) ( 1 Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606. ( 2 Change relates to long-term deferred revenue related to the extended warranties not 606. ( 3 Change relates to cumulative effect adjustment upon adoption of ASC 606.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the FDA or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2018, one 21% December 31, 2017, two 35% There are no 10% December 31, 2018 2017. As of December 31, 2018, three 54% December 31, 2017, two 57%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $284,000 $221,000 December 31, 2018 2017,
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2018 $3,232,000 $887,000 December 31, 2017 $1,990,000 $40,000 first first not As part of the Company’s normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2018 2017.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2018 2017. $686,000, not December 31,2018. No December 31, 2017. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2018, not Contract Costs The Company has elected the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that the Company otherwise would have recognized is one December 31, 2018, one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. In accordance with the new revenue standard requirements, the disclosure of the impact of adoption on our consolidated statement of operations for the year ended December 31, 2018 December 31, 2018 For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (1.61 ) $ (1.63 ) $ 0.02 Weighted average shares 31,059,483 31,059,483 ( 1 Change relates to revenue from extended assurance warranties for which no 606. ( 2 Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606. ( 3 Change relates to the net gain adjustment on the adoption of ASC 606. As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3) ( 1 Change relates to the current portion of deferred revenue in connection with the extended warranties not 606, 606. ( 2 Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not 606. ( 3 Change relates to $177,000 606 $749,000 December 31, 2018. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). Year Ended December 31, 2018 2017 United States $ 13,606 11,004 Asia Pacific 2,891 3,178 Europe and Middle East 1,369 667 Canada 563 79 Latin America 51 360 Other 37 - Total $ 18,517 $ 15,288 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments are reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2018 2017, no
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Advertising Costs, Policy [Policy Text Block]	Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2018 2017.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company’s deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2018 2017. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2018 2017,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Year Ended December 31, 2018 2017 Stock options to purchase common stock 4,014,475 2,694,224 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 57,500 10,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In February 2016, No. 2016 02, 842 December 15, 2018, July 2018, January 1, 2019, 12 not In August 2016, No. 2016 15, 230 zero December 15, 2017, January 1, 2018 not In August 2016, No. 2016 18, 230 December 15, 2017, January 1, 2018 not In May 2017, No. 2017 09, 718 may 718. December 15, 2017, January 1, 2018 not In June 2018, 2018 07, 718 718 718 December 15, 2018, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Balance as of December 31, 2017 Adjustment Due to Adoption of ASC 606 Balance as of January 1, 2018 Consolidated Balance Sheet: Liabilities Accrued liabilities $ 4,605 $ 18 (1) $ 4,623 Other noncurrent liabilities $ 327 $ (195 ) (2) $ 132 Equity Accumulated deficit $ (105,581 ) $ 177 (3) $ (105,404 )
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	For the year ended December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Statement of Operations Revenue $ 18,517 $ 17,780 $ 737 (1) Cost of revenue $ 11,197 $ 11,209 $ (12 ) (2) Gross profit $ 7,320 $ 6,571 $ 749 (3) Loss from operations $ (44,965 ) $ (45,714 ) $ 749 (3) Comprehensive and net loss $ (49,981 ) $ (50,730 ) $ 749 (3) Net loss per share: Basic and diluted $ (1.61 ) $ (1.63 ) $ 0.02 Weighted average shares 31,059,483 31,059,483 As of December 31, 2018 As Reported Balances Without Adoption of ASC 606 Effect of Change Consolidated Balance Sheets Liabilities Accrued liabilities $ 6,766 $ 7,014 $ (248 ) (1) Other noncurrent liabilities $ 634 $ 1,313 $ (679 ) (2) Equity Accumulated deficit $ (155,385 ) $ (156,311 ) $ 926 (3)
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2018 2017 United States $ 13,606 11,004 Asia Pacific 2,891 3,178 Europe and Middle East 1,369 667 Canada 563 79 Latin America 51 360 Other 37 - Total $ 18,517 $ 15,288
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2018 2017 Stock options to purchase common stock 4,014,475 2,694,224 Warrants to purchase common stock 642,622 642,622 Restricted common stock awards 57,500 10,000

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	Life December 31, (in years) 2018 2017 Medical equipment 5 $ 3,571 $ 1,299 Computer equipment 3 309 193 Leasehold Improvements 3 121 200 Furniture and fixtures 7 403 340 Software 3 25 - 4,429 2,032 Less: Accumulated depreciation and amortization (1,513 ) (729 ) Property and equipment, net $ 2,916 $ 1,303

Note 6 - Accrued Liabilities (T

Note 6 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, December 31, 2018 2017 Accrued sales commission $ 1,743 $ 1,067 Accrued professional fees 978 562 Accrued bonuses 837 1,597 Accrued interest 683 447 Customer contracts liabilities 686 - Accrued payroll and other related expenses 877 488 Travel and entertainment 280 156 Accrued sales & use tax 259 149 Accrued clinical trial costs 84 30 Other accruals 339 109 Total accrued liabilities $ 6,766 $ 4,605

Note 7 - Note Payable (Tables)

Note 7 - Note Payable (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2019 $ 2,778 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 47,878 Less: Amount representing interest (16,127 ) Present value of obligations 31,751 Less: Unamortized debt discount (1,223 ) Note payable, noncurrent portion $ 30,528

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending December 31, 2019 $ 296 2020 143 2021 23 Total minimum lease payments $ 462

Note 9 - Common Stock (Tables)

Note 9 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants September 2014 Common Shares September 23, 2019 $ 4.24 86,831 October 2014 Common Shares October 13, 2019 $ 4.24 29,000 November 2014 Common Shares November 12, 2019 $ 4.24 12,500 February 2015 Common Shares February 17, 2025 $ 4.00 75,697 March 2015 Common Shares March 26, 2025 $ 2.72 1,454 May 2015 Common Shares May 12, 2025 $ 4.24 36,229 May 2015 Common Shares May 17, 2020 $ 4.24 21,585 December 2015 Common Shares December 16, 2025 $ 5.60 26,875 April 2016 Common Shares April 1, 2026 $ 6.08 25,000 May 2016 Common Shares May 11, 2021 $ 7.74 5,000 June 2016 Common Shares June 20, 2026 $ 4.98 100,402 May 2017 Common Shares May 25, 2027 $ 9.50 222,049 642,622

Note 10 - Summary of Stock Op_2

Note 10 - Summary of Stock Options (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended December 31, 2018 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, December 31, 2016 1,909,764 $ 6.19 9.1 $ 211,396 Options granted 1,000,985 $ 5.68 Options exercised (7,730 ) $ 4.02 Options canceled (208,795 ) $ 8.88 Options outstanding, December 31, 2017 2,694,224 $ 5.80 8.6 $ 249,154 Options granted 2,358,559 $ 3.52 Options exercised - $ - Options canceled (1,038,308 ) $ 5.43 Options outstanding, December 31, 2018 4,014,475 $ 4.56 7.4 $ - Vested and exercisable and expected to vest, end of period 3,825,887 $ 4.98 7.3 $ - Vested and exercisable, end of period 1,637,474 $ 5.44 5.0 $ -
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices Dec 31, 2018 Price Term (Years) Dec 31, 2018 Price $1.75 - $1.97 535,000 $ 1.95 9.4 50,000 $ 1.97 $2.02 - $2.83 180,000 $ 2.40 9.4 11,459 $ 1.97 $3.03 - $3.82 546,876 $ 3.53 9.1 64,090 $ 2.64 $4.30 - $4.97 1,247,318 $ 4.54 7.3 503,934 $ 3.76 $5.01 - $5.67 693,067 $ 5.36 6.8 397,466 $ 4.62 $6.00 - $6.61 490,470 $ 6.04 4.1 412,662 $ 5.34 $7.00 - $7.92 283,599 $ 7.65 7.4 159,718 $ 6.02 $9.92 38,135 $ 9.92 1.3 38,135 $ 7.66 $59.60 - $149.04 10 $ 149.04 2.8 10 $ 9.92 4,014,475 $ 4.56 7.4 1,637,474 $ 5.44
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2018 2017 Expected term (in years) 5 5 Average volatility 73% 59% Risk-free interest rate 2.65% 1.89% Dividend yield 0% 0% Year Ended December 31, 2018 2017 Expected term (in years) 9 10 Average volatility 69% 72% Risk-free interest rate 2.69% 2.38% Dividend yield 0% 0%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended December 31, 2018 2017 Cost of revenue $ 69 $ 19 Research and development 328 252 Selling, general and administrative 2,638 1,601 Total $ 3,035 $ 1,872
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2018 2017 Expected term (in years) 0.25 0.25 Average volatility 72% 61% Risk-free interest rate 1.92% 1.06% Dividend yield 0% 0%

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2018 2017 Income tax provision (benefit) at statutory rate (21 )% (34 )% State income taxes, net of federal benefit (4 )% (4 )% Change in valuation allowance 23 % 4 % Effect of tax legislation 0 % 33 % Other 2 % 1 % Effective tax rate 0 % 0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 31,759 $ 19,699 Capitalized start up costs 3,555 3,963 Research and development credits 951 835 Accruals and reserves 1,272 1,403 Fixed assets and depreciation 69 39 Total deferred tax assets 37,606 25,939 Valuation allowance (37,606 ) (25,939 ) Net deferred tax assets $ - $ -
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	Year Ended December 31, 2018 2017 Balance at the beginning of the year $ 397 $ 268 Additions based upon tax positions related to the current year 53 129 Balance at the end of the year $ 450 $ 397

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	Year Ended December 31, 2018 2017 United States $ 2,851 $ 1,192 Asia Pacific 24 52 Canada 28 46 Latin America 5 12 Europe 8 1 Total $ 2,916 $ 1,303

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Feb. 12, 2018	Nov. 08, 2017	Mar. 22, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Jun. 08, 2018	Jan. 01, 2018	Dec. 31, 2016
Shares Issued, Price Per Share									$ 2.56
Proceeds from Issuance of Common Stock						$ 53,792,000	$ 31,565,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance				$ 29,523,000	$ 20,730,000	29,523,000	20,730,000	$ 29,523,000			$ 8,086,000
Working Capital				31,144,000		31,144,000		31,144,000
Net Cash Provided by (Used in) Operating Activities, Total						(43,090,000)	(34,853,000)
Retained Earnings (Accumulated Deficit), Ending Balance				$ (155,385,000)	$ (105,581,000)	$ (155,385,000)	$ (105,581,000)	$ (155,385,000)		$ (105,404,000)
December 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues				14,728,504
Shares Issued, Price Per Share				$ 1.50		$ 1.50		$ 1.50
Proceeds from Issuance of Common Stock				$ 22,093,000
Proceeds From Issuance of Common Stock, Net				$ 20,385,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues	11,500,000
Shares Issued, Price Per Share	$ 3
Proceeds from Issuance of Common Stock	$ 34,500,000
Proceeds From Issuance of Common Stock, Net	$ 32,214,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues					59,249	277,249	59,249	336,498
Proceeds From Issuance of Common Stock, Net						$ 1,193,000	$ 125,000	$ 1,318,000
Aggregate Offering Price		$ 25,000,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues			8,625,000
Shares Issued, Price Per Share			$ 4
Proceeds from Issuance of Common Stock			$ 34,500,000
Proceeds From Issuance of Common Stock, Net			$ 31,440,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)		12 Months Ended
		Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2018USD ($)
Retained Earnings (Accumulated Deficit), Ending Balance		$ (155,385,000)	$ (105,581,000)	$ (105,404,000)
Other Liabilities, Noncurrent, Total		634,000	327,000	132,000
Accrued Liabilities, Current, Total		$ 6,766,000	4,605,000	4,623,000
Number of Financial Institutions		1
Allowance for Doubtful Accounts Receivable, Ending Balance		$ 284,000	221,000
Inventory, Finished Goods, Net of Reserves		3,232,000	1,990,000
Inventory, Raw Materials, Net of Reserves		887,000	40,000
Contract with Customer, Asset, Net, Total		0	0
Contract with Customer, Liability, Total		686,000	0
Gross Profit, Total		7,320,000	$ 7,444,000
Equity Method Investment, Other than Temporary Impairment		$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Warranty Period		1 year
Maximum [Member]
Property, Plant and Equipment, Useful Life		7 years
Warranty Period		3 years
Medical Equipment, Sales Demos [Member]
Property, Plant and Equipment, Useful Life		5 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Number of Customers		1	2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | One Customer [Member]
Concentration Risk, Percentage		21.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Two Customers [Member]
Concentration Risk, Percentage			35.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers		3	2
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage			57.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage		54.00%
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance	[1]			177,000
Other Liabilities, Noncurrent, Total	[2]			(195,000)
Accrued Liabilities, Current, Total	[3]			$ 18,000
Gross Profit, Total		$ 749,000
[1]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[2]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[3]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($)		Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Accrued liabilities		$ 6,766,000	$ 4,623,000	$ 4,605,000
Other noncurrent liabilities		634,000	132,000	327,000
Accumulated deficit		$ (155,385,000)	(105,404,000)	$ (105,581,000)
Accounting Standards Update 2014-09 [Member]
Accrued liabilities	[1]		18,000
Other noncurrent liabilities	[2]		(195,000)
Accumulated deficit	[3]		$ 177,000
[1]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[2]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[3]	Change relates to cumulative effect adjustment upon adoption of ASC 606.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Impact of New Standard on Consolidated Balance Sheet and Consolidated Statements of Operations (Details) - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2018
Revenue		$ 18,517,000	$ 15,288,000
Cost of revenue		11,197,000	7,844,000
Gross profit		7,320,000	7,444,000
Loss from operations		(44,965,000)	(33,730,000)
Comprehensive and net loss		$ (49,981,000)	$ (36,959,000)
Basic and diluted (in dollars per share)		$ (1.61)	$ (2.11)
Weighted average shares (in shares)		31,059,483	17,496,942
Accrued liabilities		$ 6,766,000	$ 4,605,000	$ 4,623,000
Other noncurrent liabilities		634,000	327,000	132,000
Accumulated deficit		(155,385,000)	$ (105,581,000)	(105,404,000)
Accounting Standards Update 2014-09 [Member]
Gross profit		749,000
Accrued liabilities	[1]			18,000
Other noncurrent liabilities	[2]			(195,000)
Accumulated deficit	[3]			$ 177,000
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue		17,780,000
Cost of revenue		11,209,000
Gross profit		6,571,000
Loss from operations		(45,714,000)
Comprehensive and net loss		$ (50,730,000)
Basic and diluted (in dollars per share)		$ (1.63)
Weighted average shares (in shares)		31,059,483
Accrued liabilities		$ 7,014,000
Other noncurrent liabilities		1,313,000
Accumulated deficit		(156,311,000)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue	[4]	737,000
Cost of revenue	[5]	(12,000)
Gross profit	[6]	749,000
Loss from operations	[6]	749,000
Comprehensive and net loss	[6]	$ 749,000
Basic and diluted (in dollars per share)	[6]	$ 0.02
Weighted average shares (in shares)
Accrued liabilities	[7]	$ (248,000)
Other noncurrent liabilities	[8]	(679,000)
Accumulated deficit	[9]	$ 926,000
[1]	Change relates to future costs associated with extended warranties required to be recorded on adoption of ASC 606.
[2]	Change relates to long-term deferred revenue related to the extended warranties not required to be recorded under ASC 606.
[3]	Change relates to cumulative effect adjustment upon adoption of ASC 606.
[4]	Change relates to revenue from extended assurance warranties for which no deferral is required on the adoption of ASC 606.
[5]	Change relates to the future costs associated with extended assurance warranties required to be recorded on the adoption of ASC 606.
[6]	Change relates to the net gain adjustment on the adoption of ASC 606.
[7]	Change relates to future costs associated with extended warranties required to be recorded on the adoption of ASC 606, partially offset by the current portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[8]	Change relates to noncurrent portion of deferred revenue in connection with the extended warranties not required to be recorded under ASC 606.
[9]	Change relates to $177,000 cumulative effect adjustment on the adoption of ASC 606 and the net gain adjustment of $749,000 for the year ended December 31, 2018.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 18,517	$ 15,288
UNITED STATES
Revenue	13,606	11,004
Asia Pacific [Member]
Revenue	2,891	3,178
Europe And Middle East [Member]
Revenue	1,369	667
CANADA
Revenue	563	79
Latin America [Member]
Revenue	51	360
Other [Member]
Revenue	$ 37

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee Stock Option [Member]
Stock options to purchase common stock (in shares)	4,014,475	2,694,224
Common Stock Warrants [Member]
Stock options to purchase common stock (in shares)	642,622	642,622
Restricted Stock [Member]
Stock options to purchase common stock (in shares)	57,500	10,000

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Depreciation, Total	$ 786,000	$ 449,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 4,429	$ 2,032
Less: Accumulated depreciation and amortization	(1,513)	(729)
Property and equipment, net	$ 2,916	1,303
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Property and equipment, gross	$ 3,571	1,299
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 309	193
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 121	200
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Property and equipment, gross	$ 403	340
Software [Member]
Property, Plant and Equipment, Useful Life	3 years
Property and equipment, gross	$ 25

Note 5 - Investment in Limite_2

Note 5 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018USD ($)
Payments to Acquire Equity Method Investments			$ 2,500,000
Income (Loss) from Equity Method Investments, Total		$ (657,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		9.00%		9.00%
Income (Loss) from Equity Method Investments, Total		$ (657,000)
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		3,300	1,200	4,500
Payments for Purchase of Products		$ 327,000	$ 89,000	$ 416,000
Payments for Product Related Costs		$ 337,000	$ 94,000
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 6 - Accrued Liabilities -

Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Accrued sales commission	$ 1,743		$ 1,067
Accrued professional fees	978		562
Accrued bonuses	837		1,597
Accrued interest	683		447
Customer contracts liabilities	686
Accrued payroll and other related expenses	877		488
Travel and entertainment	280		156
Accrued sales & use tax	259		149
Accrued clinical trial costs	84		30
Other accruals	339		109
Total accrued liabilities	$ 6,766	$ 4,623	$ 4,605

Note 7 - Note Payable (Details

Note 7 - Note Payable (Details Textual) - USD ($)	May 22, 2017	Jun. 20, 2016	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			642,622
Interest Payable			$ 16,127,000
Notes Payable, Noncurrent, Total			$ 30,528,000	$ 28,948,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Warrant Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		100,402	100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 4.98	$ 4.98
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	222,049		222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.50		$ 9.50
Warrants and Rights Outstanding, Term	10 years
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member]
Debt Instrument, Face Amount		$ 10,000,000
Debt Instrument, Fee, Percentage		4.00%
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | First Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 7,500,000
The 2016 Loan Agreement [Member] | Western Alliance Bank [Member] | Second Tranche [Member]
Proceeds from Issuance of Long-term Debt, Total		$ 2,500,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount	$ 20,000,000
Debt Agreement, Covenant, Additional Funding	10,000,000
Debt Agreement, Maximum Borrowing Capacity	$ 30,000,000
Debt Instrument, Term	6 years
Debt instrument, Interest Only Payment, Period	4 years
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period	4.00%
Paid-in-Kind Interest			$ 1,256,000	495,000
Debt Instrument, Prepayment Fee, Percentage	5.00%
Debt Instrument, Prepayment Fee, Period of Term	5 years
Debt Instrument, Covenant, Cash and Cash Equivalents	$ 2,000,000
Notes Payable, Noncurrent, Total			30,528,000	$ 28,948,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable			$ 484,000

Note 7 - Note Payable - Summary

Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
2019	$ 2,778
2020	2,901
2021	16,673
2022	19,306
2023	6,220
Total payments	47,878
Less: Amount representing interest	(16,127)
Present value of obligations	31,751
Less: Unamortized debt discount	(1,223)
Note payable, noncurrent portion	$ 30,528	$ 28,948

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual)	1 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Feb. 01, 2017USD ($)ft²$ / item
Operating Leases, Rent Expense, Total		$ 358,000	$ 442,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²				12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | $ / item				20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | $ / item				21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | $ / item				21.75
Security Deposit				$ 22,000
Operating Leases, Allowance for Certain Improvements				$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract	3 years
Operating Leases, Monthly Payment	$ 3,000

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 296
2020	143
2021	23
Total minimum lease payments	$ 462

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual)	Jun. 08, 2018USD ($)$ / sharesshares	Feb. 12, 2018USD ($)$ / sharesshares	Nov. 08, 2017USD ($)	Mar. 22, 2017USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	May 19, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	May 22, 2017USD ($)yr$ / sharesshares	Jun. 20, 2016USD ($)$ / sharesshares
Shares Issued, Price Per Share | $ / shares	$ 2.56
Proceeds from Issuance of Common Stock								$ 53,792,000	$ 31,565,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares	100,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 256,000							$ 336,000	$ 226,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					642,622			642,622		642,622
Debt Instrument, Unamortized Discount, Total					$ 1,223,000			$ 1,223,000		$ 1,223,000
Class of Warrants or Rights, Exercises in Period | shares								0	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares								0	0
Allocated Share-based Compensation Expense, Total								$ 3,035,000	$ 1,872,000
The 2016 Loan Agreement [Member]
Debt Issuance Costs, Net, Total												$ 90,000
Amortization of Debt Discount (Premium)									371,000
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total							$ 790,000		790,000
Amortization of Debt Discount (Premium)								325,000	183,000
Debt Instrument, Unamortized Discount, Total					$ 1,223,000			$ 1,223,000		$ 1,223,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					100,402			100,402		100,402		100,402
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 4.98			$ 4.98		$ 4.98		$ 4.98
Warrants and Rights Outstanding												$ 350,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					222,049			222,049		222,049	222,049
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 9.50			$ 9.50		$ 9.50	$ 9.50
Warrants and Rights Outstanding											$ 940,000
Warrants and Rights Outstanding, Term											10 years
Allocated Share-based Compensation Expense, Total								$ 0	$ 0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input											0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input											0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr											10
Restricted Stock [Member]
Stock Issued During Period, Shares, New Issues | shares						35,000
Shares Issued, Price Per Share | $ / shares						$ 7.42
Stock Issued During Period, Value, New Issues						$ 260,000
December 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares					14,728,504
Shares Issued, Price Per Share | $ / shares					$ 1.50			$ 1.50		$ 1.50
Proceeds from Issuance of Common Stock					$ 22,093,000
Proceeds From Issuance of Common Stock, Net					$ 20,385,000
Stock Issued During Period, Value, New Issues								$ 20,385,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares		11,500,000
Shares Issued, Price Per Share | $ / shares		$ 3
Proceeds from Issuance of Common Stock		$ 34,500,000
Proceeds From Issuance of Common Stock, Net		$ 32,214,000
Stock Issued During Period, Value, New Issues								$ 32,214,000
November 2017 ATM Facility [Member]
Stock Issued During Period, Shares, New Issues | shares							59,249	277,249	59,249	336,498
Proceeds From Issuance of Common Stock, Net								$ 1,193,000	$ 125,000	$ 1,318,000
Aggregate Offering Price			$ 25,000,000
Stock Issued During Period, Value, New Issues								$ 1,193,000	125,000
March 2017 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares				8,625,000
Shares Issued, Price Per Share | $ / shares				$ 4
Proceeds from Issuance of Common Stock				$ 34,500,000
Proceeds From Issuance of Common Stock, Net				$ 31,440,000
Stock Issued During Period, Value, New Issues									$ 31,440,000

Note 9 - Common Stock - Summary

Note 9 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	May 22, 2017	Jun. 20, 2016
Shares Outstanding Under Warrants (in shares)	642,622
September 2014 Issuance Through Private Offering [Member]
Expiration Date	Sep. 23, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	86,831
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	29,000
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	12,500
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 4
Shares Outstanding Under Warrants (in shares)	75,697
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 2.72
Shares Outstanding Under Warrants (in shares)	1,454
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	36,229
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 4.24
Shares Outstanding Under Warrants (in shares)	21,585
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 5.60
Shares Outstanding Under Warrants (in shares)	26,875
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 6.08
Shares Outstanding Under Warrants (in shares)	25,000
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 7.74
Shares Outstanding Under Warrants (in shares)	5,000
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 4.98		$ 4.98
Shares Outstanding Under Warrants (in shares)	100,402		100,402
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 9.50	$ 9.50
Shares Outstanding Under Warrants (in shares)	222,049	222,049

Note 10 - Summary of Stock Op_3

Note 10 - Summary of Stock Options (Details Textual) - USD ($)	Sep. 28, 2018	Jun. 29, 2018	May 30, 2018	Mar. 29, 2018	Dec. 23, 2016	Aug. 22, 2016	Dec. 31, 2018	Oct. 31, 2018	Jul. 31, 2018	Jun. 30, 2018	Apr. 30, 2018	Jan. 31, 2018	Dec. 31, 2017	Oct. 31, 2017	Sep. 30, 2017	May 31, 2017	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2018	Jun. 08, 2018	Dec. 06, 2017	Dec. 05, 2017	Aug. 15, 2017	Aug. 14, 2017	May 19, 2017	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance							4,014,475						2,694,224				4,014,475	4,014,475	2,694,224	1,909,764	4,014,475
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance							$ 4.56						$ 5.80				$ 4.56	$ 4.56	$ 5.80	$ 6.19	$ 4.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																		7 years 146 days	8 years 219 days	9 years 36 days
Shares Issued, Price Per Share																						$ 2.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,358,559	1,000,985
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																			7,730
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value																			$ 31,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																		0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 4,328,328										$ 4,328,328	$ 4,328,328			$ 4,328,328
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition																		2 years 262 days
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																		0.00%	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost			$ 97,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																		0.00%
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																		57,500
Shares Issued, Price Per Share																											$ 7.42
Restricted Stock [Member] | Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										2 years		1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										50,000		25,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 3.58		$ 5.19
Restricted Stock [Member] | Consultant [Member] | June 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																		0
Restricted Stock [Member] | Consultant [Member] | January 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																		25,000
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance							38,145										38,145	38,145			38,145
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							0										0	0			0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance							$ 9.96										$ 9.96	$ 9.96			$ 9.96
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																		1 year 109 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance							3,976,330										3,976,330	3,976,330			3,976,330
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance							$ 4.50										$ 4.50	$ 4.50			$ 4.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																		7 years 182 days
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum																		10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent																		110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock						4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					2,523,209		4,914,016										4,914,016	4,914,016			4,914,016		4,914,016	4,000,000	4,000,000	2,523,209		2,000,000
Common Stock, Capital Shares Reserved for Future Issuance							603,712										603,712	603,712			603,712
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		2,146,171	981,110
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																		$ 2.24	$ 2.88
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																		0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																		212,388	19,875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value																		$ 1.62	$ 4.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																		0	0
The 2013 Plan [Member] | Restricted Stock [Member] | Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period							40,775	17,985	18,278		14,672	9,637		7,884	6,947	4,797
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 1.05	$ 2.48	$ 2.63		$ 3.44	$ 5.19		$ 5.55	$ 5.58	$ 7.07
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period							40,775	17,985	18,278		14,672	9,637		7,884	6,947	4,797
The 2013 Plan [Member] | Restricted Stock [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period													4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period													10,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value													$ 4.94
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period																					2,500
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																		5 years
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	28,698	25,618		20,744													50,727
Employee Stock Purchase Plan, Purchase Price	$ 2.24	$ 2.31		$ 3.11			$ 0.89										$ 0.89	$ 0.89			$ 0.89
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares							256,319										256,319	256,319			256,319
Shares Issued, Price Per Share							$ 0.89						$ 1.51				$ 0.89	$ 0.89	$ 1.51		$ 0.89
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																		0.00%	0.00%

Note 10 - Summary of Stock Op_4

Note 10 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Options outstanding, Shares (in shares)	2,694,224	1,909,764
Options outstanding, Weighted average exercise price (in dollars per share)	$ 5.80	$ 6.19
Options outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 146 days	8 years 219 days	9 years 36 days
Options outstanding, Aggregate Intrinsic Value		$ 249,154	$ 211,396
Options granted, Shares (in shares)	2,358,559	1,000,985
Options granted, Weighted average exercise price (in dollars per share)	$ 3.52	$ 5.68
Options exercised, Shares (in shares)		(7,730)
Options exercised, Weighted average exercise price (in dollars per share)		$ 4.02
Options canceled, Shares (in shares)	(1,038,308)	(208,795)
Options canceled, Weighted average exercise price (in dollars per share)	$ 5.43	$ 8.88
Options outstanding, Shares (in shares)	4,014,475	2,694,224	1,909,764
Options outstanding, Weighted average exercise price (in dollars per share)	$ 4.56	$ 5.80	$ 6.19
Vested and exercisable and expected to vest, end of period, Number Of Shares (in shares)	3,825,887
Vested and exercisable and expected to vest, end of period, Weighted Average Exercise Price (in dollars per share)	$ 4.98
Vested and exercisable and expected to vest, end of period, Weighted Average Remaining Contractual Term (Year)	7 years 109 days
Vested and exercisable, end of period, Number Of Shares (in shares)	1,637,474
Vested and exercisable, end of period, Weighted Average Exercise Price (in dollars per share)	$ 5.44
Vested and exercisable, end of period, Weighted Average Remaining Contractual Term (Year)	5 years

Note 10 - Summary of Stock Op_5

Note 10 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Options outstanding, number (in shares) | shares	4,014,475
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.56
Options outstanding, weighted average remaining contractual term (Year)	7 years 146 days
Options exercisable, number exercisable (in shares) | shares	1,637,474
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.44
Range One [Member]
Exercise price range, lower limit (in dollars per share)	1.75
Exercise price range, upper limit (in dollars per share)	$ 1.97
Options outstanding, number (in shares) | shares	535,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 1.95
Options outstanding, weighted average remaining contractual term (Year)	9 years 146 days
Options exercisable, number exercisable (in shares) | shares	50,000
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.97
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	2.02
Exercise price range, upper limit (in dollars per share)	$ 2.83
Options outstanding, number (in shares) | shares	180,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.40
Options outstanding, weighted average remaining contractual term (Year)	9 years 146 days
Options exercisable, number exercisable (in shares) | shares	11,459
Options exercisable, weighted average exercise price (in dollars per share)	$ 1.97
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	3.03
Exercise price range, upper limit (in dollars per share)	$ 3.82
Options outstanding, number (in shares) | shares	546,876
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.53
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days
Options exercisable, number exercisable (in shares) | shares	64,090
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.64
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	4.30
Exercise price range, upper limit (in dollars per share)	$ 4.97
Options outstanding, number (in shares) | shares	1,247,318
Options outstanding, weighted average exercise price (in dollars per share)	$ 4.54
Options outstanding, weighted average remaining contractual term (Year)	7 years 109 days
Options exercisable, number exercisable (in shares) | shares	503,934
Options exercisable, weighted average exercise price (in dollars per share)	$ 3.76
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	5.01
Exercise price range, upper limit (in dollars per share)	$ 5.67
Options outstanding, number (in shares) | shares	693,067
Options outstanding, weighted average exercise price (in dollars per share)	$ 5.36
Options outstanding, weighted average remaining contractual term (Year)	6 years 292 days
Options exercisable, number exercisable (in shares) | shares	397,466
Options exercisable, weighted average exercise price (in dollars per share)	$ 4.62
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	6
Exercise price range, upper limit (in dollars per share)	$ 6.61
Options outstanding, number (in shares) | shares	490,470
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.04
Options outstanding, weighted average remaining contractual term (Year)	4 years 36 days
Options exercisable, number exercisable (in shares) | shares	412,662
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.34
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	7
Exercise price range, upper limit (in dollars per share)	$ 7.92
Options outstanding, number (in shares) | shares	283,599
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.65
Options outstanding, weighted average remaining contractual term (Year)	7 years 146 days
Options exercisable, number exercisable (in shares) | shares	159,718
Options exercisable, weighted average exercise price (in dollars per share)	$ 6.02
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	9.92
Exercise price range, upper limit (in dollars per share)	$ 9.92
Options outstanding, number (in shares) | shares	38,135
Options outstanding, weighted average exercise price (in dollars per share)	$ 9.92
Options outstanding, weighted average remaining contractual term (Year)	1 year 109 days
Options exercisable, number exercisable (in shares) | shares	38,135
Options exercisable, weighted average exercise price (in dollars per share)	$ 7.66
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	59.60
Exercise price range, upper limit (in dollars per share)	$ 149.04
Options outstanding, number (in shares) | shares	10
Options outstanding, weighted average exercise price (in dollars per share)	$ 149.04
Options outstanding, weighted average remaining contractual term (Year)	2 years 292 days
Options exercisable, number exercisable (in shares) | shares	10
Options exercisable, weighted average exercise price (in dollars per share)	$ 9.92

Note 10 - Summary of Stock Op_6

Note 10 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected term (Year)	5 years	5 years
Average volatility	73.00%	59.00%
Risk-free interest rate	2.65%	1.89%
Dividend yield	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days
Average volatility	72.00%	61.00%
Risk-free interest rate	1.92%	1.06%
Dividend yield	0.00%	0.00%

Note 10 - Summary of Stock Op_7

Note 10 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected term (Year)	5 years	5 years
Average volatility	73.00%	59.00%
Risk-free interest rate	2.65%	1.89%
Dividend yield	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)	9 years	10 years
Average volatility	69.00%	72.00%
Risk-free interest rate	2.69%	2.38%
Dividend yield	0.00%	0.00%

Note 10 - Summary of Stock Op_8

Note 10 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock-based compensation expense	$ 3,035	$ 1,872
Cost of Sales [Member]
Stock-based compensation expense	69	19
Research and Development Expense [Member]
Stock-based compensation expense	328	252
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 2,638	$ 1,601

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Expense (Benefit), Total	$ 0
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	11,667,000	$ 1,501,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	951,000	835,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0
Unrecognized Tax Benefits, Ending Balance	$ 450,000	$ 397,000	$ 268,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	34.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 126,893,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	830,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	97,677,000
Deferred Tax Assets, Tax Credit Carryforwards, Research	$ 668,000

Note 11 - Income Taxes - Provis

Note 11 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income tax provision (benefit) at statutory rate	(21.00%)	(34.00%)
State income taxes, net of federal benefit	(4.00%)	(4.00%)
Change in valuation allowance	23.00%	4.00%
Effect of tax legislation	0.00%	33.00%
Other	2.00%	1.00%
Effective tax rate	0.00%	0.00%

Note 11 - Income Taxes - Signif

Note 11 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Net operating loss carryforwards	$ 31,759	$ 19,699
Capitalized start up costs	3,555	3,963
Research and development credits	951	835
Accruals and reserves	1,272	1,403
Fixed assets and depreciation	(69)	(39)
Total deferred tax assets	37,606	25,939
Valuation allowance	(37,606)	(25,939)
Net deferred tax assets

Note 11 - Income Taxes - Unreco

Note 11 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 397,000	$ 268,000
Additions based upon tax positions related to the current year	53,000	129,000
Balance	$ 450,000	$ 397,000

Note 12 - Related Party Trans_3

Note 12 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	12 Months Ended		135 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018
Stock Issued During Period, Shares, New Issues			37,500
Related Party Transaction, Amounts of Transaction	$ 10,150,000	$ 7,912,000

Note 12 - Related Party Trans_4

Note 12 - Related Party Transactions - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Long-lived assets	$ 2,916	$ 1,303
UNITED STATES
Long-lived assets	2,851	1,192
Asia Pacific [Member]
Long-lived assets	24	52
CANADA
Long-lived assets	28	46
Latin America [Member]
Long-lived assets	5	12
Europe [Member]
Long-lived assets	$ 8	$ 1

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - The 2013 Plan [Member] - shares	Jan. 01, 2019	Dec. 23, 2016	Dec. 31, 2018	Dec. 06, 2017	Dec. 05, 2017	Aug. 15, 2017	Aug. 14, 2017	Dec. 22, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		523,209
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		2,523,209	4,914,016	4,914,016	4,000,000	4,000,000	2,523,209	2,000,000
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,043,142
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	6,957,158